A Study Comparing the Cardiovascular (CV) Safety Associated with the Use of Canagliflozin Versus Other Non-Gliflozin Antidiabetic Agents in Type 2 Diabetes Mellitus (T2DM) Patients

Trial Profile

A Study Comparing the Cardiovascular (CV) Safety Associated with the Use of Canagliflozin Versus Other Non-Gliflozin Antidiabetic Agents in Type 2 Diabetes Mellitus (T2DM) Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Canagliflozin (Primary) ; CD26 antigen inhibitors; Glucagon like peptide 1 receptor agonists; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2017 New trial record
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top